Fitabeo Therapeutics

10:30 AM - 10:45 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Fitabeo Therapeutics is a specialty pharmaceutical company, developing a diversified portfolio of medicines to address unmet needs in the areas of Palliative care, Drug overdose/addiction, and Women’s health. Our vision is to enhance the quality of life for patients and their families by providing convenient and compliant non-invasive medicines.

Combined Total addressable market for the three treatment areas that our pipeline focuses on is $184bn.

The founding team has the experience and expertise in drug development across different delivery technologies and commercialising over 10 products across geographies and are supported by a well reputed global advisory board.

FTx filed one patent in 2018 that is currently in examination across the national phase territories and will file two patents in March 2023.

FTx's first two lead programs will complete phase IIb study in May with launch planned in 2025. FTx has expressions of interest from five potential partners.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
FTx100 & FTx200
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder and CEO
Fitabeo Therapeutics